Review: Endocannabinoid System Could Address IBD Complications Beyond the Gut
A comprehensive review found the endocannabinoidome — a network of cannabinoid receptors, lipid mediators, and enzymes — shows promise for managing IBD complications in the joints, skin, liver, and eyes, not just intestinal inflammation.
Quick Facts
What This Study Found
The endocannabinoidome (eCBome) includes receptors (CB1, CB2, GPR55, GPR35, PPARα, TRPV1), lipid mediators, and metabolic enzymes that modulate immune responses, gut barrier integrity, and systemic inflammation. Targeting eCBome may improve both intestinal inflammation and extraintestinal manifestations including arthritis, liver dysfunction, and dermatological disorders.
Key Numbers
Receptors reviewed: CB1, CB2, GPR55, GPR35, PPARα, TRPV1. Extraintestinal targets: joints (arthritis), skin (dermatological disorders), liver (dysfunction), eyes. Multiple metabolic enzymes and lipid mediators assessed.
How They Did This
Comprehensive literature review across PubMed, Scopus, Web of Science, Science Direct, and Google Scholar. Focused on endocannabinoidome role in IBD and extraintestinal manifestations.
Why This Research Matters
IBD is not just a gut disease — many patients suffer from joint, skin, liver, and eye complications that standard intestinal therapies do not address. The endocannabinoidome offers a unified therapeutic target for both local and systemic disease components.
The Bigger Picture
Moving beyond the traditional focus on CB1 and CB2 receptors to the broader endocannabinoidome opens new therapeutic possibilities. Understanding the full network of cannabinoid-related signaling could lead to more targeted treatments with fewer side effects.
What This Study Doesn't Tell Us
Narrative review without systematic methodology. Much evidence is preclinical. Clinical evidence for eCBome-targeting therapies in IBD extraintestinal manifestations is very limited. Complex system makes targeted drug development challenging.
Questions This Raises
- ?Which eCBome targets are most clinically promising for IBD extraintestinal complications?
- ?Could a single eCBome-targeting drug address both intestinal and extraintestinal IBD?
Trust & Context
- Key Stat:
- Evidence Grade:
- Comprehensive narrative review identifying promising targets, but most evidence is preclinical and clinical validation is minimal.
- Study Age:
- 2025 publication.
- Original Title:
- Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease.
- Published In:
- Pharmaceuticals (Basel, Switzerland), 18(4) (2025)
- Authors:
- Thapa, Dinesh(5), Ghimire, Anjali, Warne, Leon N(5), Carlessi, Rodrigo
- Database ID:
- RTHC-07788
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Can cannabinoids help with IBD joint pain?
This review found the endocannabinoidome plays a role in modulating joint inflammation and could potentially address IBD-related arthritis. However, clinical evidence for this specific application is still very limited.
Why does IBD cause problems outside the gut?
IBD involves systemic immune dysregulation, causing complications in joints, skin, liver, and eyes. This review found the endocannabinoidome — a network including CB1, CB2, and other receptors — regulates both gut and systemic inflammation, making it a promising target for comprehensive IBD treatment.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
- cannabis-and-ibs-gut-health-inflammation
- cannabis-and-crohns-disease-gastroenterology
Cite This Study
https://rethinkthc.com/research/RTHC-07788APA
Thapa, Dinesh; Ghimire, Anjali; Warne, Leon N; Carlessi, Rodrigo. (2025). Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease.. Pharmaceuticals (Basel, Switzerland), 18(4). https://doi.org/10.3390/ph18040478
MLA
Thapa, Dinesh, et al. "Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease.." Pharmaceuticals (Basel, 2025. https://doi.org/10.3390/ph18040478
RethinkTHC
RethinkTHC Research Database. "Targeting the Endocannabinoidome: A Novel Approach to Managi..." RTHC-07788. Retrieved from https://rethinkthc.com/research/thapa-2025-targeting-the-endocannabinoidome-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.